BD launches new knife range

Article

The BD range of Atomic Edge Limbal Relaxing Incision (LRI) knives for surgical correction of astigmatism has been launched by BD Medical. The knives, which feature a retractable safety shield, use single-crystal silicon, offering high performance at low cost.

The BD range of Atomic Edge Limbal Relaxing Incision (LRI) knives for surgical correction of astigmatism has been launched by BD Medical. The knives, which feature a retractable safety shield, use single-crystal silicon, offering high performance at low cost.

A study conducted in 2007 compared the single-use BD Atomic Edge LRI knives with a single-use metal LRI blade and a reusable diamond LRI blade. Across the five metrics evaluated (incision smoothness, corneal curvature tracking, incision control, incision quality and blade sharpness), the Atomic Edge blade performed better than the single-use metal blade, and equally as well as the reusable diamond blade. The blades were deemed “clinically acceptable” by 95% of the 65 ophthalmic surgeons surveyed.

The BD Atomic Edge LRI knives are available now.

Recent Videos
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Christiana Dinah speaks about her ASRS presentation, Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.